Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodrigo Dienstmann

Showing results (1-10 of 175) with videos related to

Pageof 18
Sort By:
ESMO Real World Data and Digital Oncology|February 6, 2026
ESMO Real-World Data and Digital Oncology: a journal to understand how health systems can help provide better cancer careRodrigo Dienstmann
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 23, 2017
Tumor Side as Model of Integrative Molecular Classification of Colorectal CancerRodrigo Dienstmann
JCO Precision Oncology|February 9, 2022
Model for Prioritizing Targetable Alterations in CancerRodrigo Dienstmann
Current Opinion in Investigational Drugs (London, England : 2000)|December 15, 2010
Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancerRodrigo Dienstmann, Josep Tabernero
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2014
TGR analysis in phase I clinical trials--letterRodrigo Dienstmann, Josep Tabernero
The Lancet. Oncology|September 2, 2022
Is upfront full molecular profiling needed in all patients with colorectal cancer in daily practice?Rodrigo Dienstmann, Sara Lonardi
Expert Opinion on Biological Therapy|June 18, 2011
Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical developmentRodrigo Dienstmann, Enriqueta Felip
ESMO Open|November 15, 2018
Precision oncology: separating the wheat from the chaffJordi Remon, Rodrigo Dienstmann
Anti-Cancer Agents in Medicinal Chemistry|March 24, 2011
BRAF as a target for cancer therapyRodrigo Dienstmann, Josep Tabernero
Nature|July 21, 2017
Cancer: A precision approach to tumour treatmentRodrigo Dienstmann, Josep Tabernero
Pageof 18

Showing results (1-10 of 175) with videos related to

Sort By:
Pageof 18
ESMO Real World Data and Digital Oncology|February 6, 2026
ESMO Real-World Data and Digital Oncology: a journal to understand how health systems can help provide better cancer careRodrigo Dienstmann
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 23, 2017
Tumor Side as Model of Integrative Molecular Classification of Colorectal CancerRodrigo Dienstmann
JCO Precision Oncology|February 9, 2022
Model for Prioritizing Targetable Alterations in CancerRodrigo Dienstmann
Current Opinion in Investigational Drugs (London, England : 2000)|December 15, 2010
Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancerRodrigo Dienstmann, Josep Tabernero
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2014
TGR analysis in phase I clinical trials--letterRodrigo Dienstmann, Josep Tabernero
The Lancet. Oncology|September 2, 2022
Is upfront full molecular profiling needed in all patients with colorectal cancer in daily practice?Rodrigo Dienstmann, Sara Lonardi
Expert Opinion on Biological Therapy|June 18, 2011
Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical developmentRodrigo Dienstmann, Enriqueta Felip
ESMO Open|November 15, 2018
Precision oncology: separating the wheat from the chaffJordi Remon, Rodrigo Dienstmann
Anti-Cancer Agents in Medicinal Chemistry|March 24, 2011
BRAF as a target for cancer therapyRodrigo Dienstmann, Josep Tabernero
Nature|July 21, 2017
Cancer: A precision approach to tumour treatmentRodrigo Dienstmann, Josep Tabernero
Pageof 18